Developer docs
API playgroundTry for free, no card

Search company profiles

USIL Therapeutics

Full company profile

uuid02c2mit

Namestring
USIL Therapeutics
Legal namestring
USIL Therapeutics S.A.
Company typeenum
Private
Founded yearint
2025
Short descriptiontext

USIL Therapeutics is a Luxembourg-based biotechnology company founded in 2025 developing first-in-class radioprotective medical countermeasures (UT-241 auto-injector and UT-242 IV infusion) for Acute Radiation Syndrome, serving defence ministries, first responders, civil protection agencies, and healthcare systems in Europe and allied regions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLuxembourg, Luxembourg
HQ citystring
Luxembourg
HQ countrystring
Luxembourg
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radioprotective countermeasures, radiation therapeutics, medical countermeasures, biodefense pharmaceuticals, radiological preparedness
Industry1 code
PRIMARYHLAIAGAJ
Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radioprotective Medical Countermeasures
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Countermeasure Sales to Government/Institutional Buyers
TypeOne Time License
Description

Revenue from selling radioprotective medical countermeasures (UT-241 and UT-242) to defence ministries, first responders, civil protection agencies, hospitals, and emergency response systems. As a pre-revenue company (founded 2025), commercial revenue is anticipated post-2029 market entry.

usil-therapeutics.com
2Licensing Royalties
TypeLicensing Royalties
Description

Portfolio of multiple patents covering a radioprotective molecule with protection across EU, US, and Japan may generate licensing revenue from third-party commercialization rights.

usil-therapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1UT-241
Description

IM Auto-Injector - a ready-to-use integral drug-device combination for rapid intramuscular administration, designed for time-critical scenarios involving first responders and exposed populations.

usil-therapeutics.com
+1 more record
Core offering1 text field

USIL Therapeutics develops first-in-class whole-body radioprotective medical countermeasures for Acute Radiation Syndrome (ARS). Its pipeline includes UT-241, a ready-to-use intramuscular auto-injector designed for rapid field deployment by first responders and military personnel, and UT-242, an intravenous formulation for prolonged hospital-based therapeutic coverage. The dual-use platform addresses both acute high-dose radiation exposure and prolonged lower-dose radiation scenarios relevant to defence, civilian preparedness, and space missions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase one pre-clinical trials completed with FDA review confirming safety for human administration
+2 more records
Product and service1 record
1UT-241 IM Auto-Injector
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

USIL Therapeutics selected by ESA for in-orbit validation mission aboard the International Space Station. The study evaluates USIL's whole-body radioprotection approach under microgravity and elevated cosmic radiation to assess stability, biological response, and performance in space-relevant conditions. ESA-funded project supports dual-use development across spaceflight, defence, and civilian preparedness.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with YURI for ISS validation mission. YURI is a Luxembourg company specializing in payloads to Low Earth Orbit. Stefan Dimitrov-Lübcke, YURI LUX Managing Director, serves as Space Advisor to USIL Therapeutics.

3French Alternative Energies and Atomic Energy Commission (CEA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TESAR project consortium partner coordinated by USIL. CEA brings expertise in alternative energies and atomic energy research. The TESAR project delivers the first universal medical countermeasure for acute radiation syndrome fully developed and manufactured within Europe.

usil-therapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

USIL holds two formal mandates within the European Commission's Joint Industrial Cooperation Forum (ICF) under HERA. TESAR project awarded multi-million EUR grant and STEP Seal under EU4Health Programme scoring 93/100. Selected participant in European Defence Fund Resilience 2026 work programme and EUDIS Business Accelerator Cohort 2.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration mentioned for ISS testing of the compound on International Space Station for potential space applications protecting astronauts and pilots.

6NATO Support and Procurement Agency (NSPA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Alignment with NATO procurement frameworks through NSPA for access to NATO-aligned stakeholders across Europe. Company positioned for institutional integration within defence coordination frameworks.

usil-therapeutics.com
7European Health Emergency Preparedness and Response Authority (HERA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ICF operates under HERA authority. USIL contributes to working groups addressing supply-chain resilience, manufacturing readiness, innovation, access, and strategic preparedness for medical countermeasures, supporting EU Medical Countermeasures Strategy implementation.

usil-therapeutics.com
Peers8 records
TypeEmerging player
Description

Soligenix is a late-stage biopharmaceutical company developing medical countermeasures for radiation injury (e.g., SGX301 for cutaneous radiation injury) and other biodefense indications. Comparable as a countermeasure-focused specialty biotech pursuing government procurement pathways, though smaller and less capitalized than USIL's institutional backers.

TypeEmerging player
Description

Tonix is developing countermeasures for radiation and biodefense indications alongside its CNS pipeline, pursuing government contracts similar to USIL's strategy. Smaller and earlier stage than USIL but operates in an overlapping medical countermeasure regulatory and procurement space.

TypeBroad incumbent
Description

Bavarian Nordic is an established vaccine and biodefense company with government stockpiling contracts (e.g., smallpox, Ebola) and European institutional backing. Comparable as a European-headquartered biodefense countermeasure supplier leveraging both EU and US procurement channels.

TypeBroad incumbent
Description

Landauer is a long-standing provider of radiation dosimetry and monitoring solutions used across medical, nuclear energy, and defence settings. Comparable as a radiation-safety incumbent serving the institutional customers USIL also targets, though via monitoring services rather than pharmaceutical countermeasures.

TypeDirect peer
Description

Humanetics is the most direct comparable, developing BIO 300, a small-molecule radioprotectant intended to address acute radiation syndrome and radiation injury for military and civilian applications. Both companies target the same ARS unmet need with similar regulatory pathways (FDA, BARDA, DoD stockpiling).

TypeBroad incumbent
Description

Emergent is a publicly traded, established biodefense company with a broad portfolio of medical countermeasures (anthrax vaccines, smallpox therapies, etc.) and deep government procurement relationships. It represents the incumbent model USIL aspires to scale into across the radiological countermeasure niche.

TypeBroad incumbent
Description

Mirion is a global incumbent in radiation safety, detection, dosimetry, and shielding products serving nuclear energy, defence, and medical markets. While Mirion sells equipment and services rather than drugs, it serves the same customer base (defence ministries, civil protection agencies, nuclear operators) and frames the broader radiation preparedness market USIL addresses.

TypeBroad incumbent
Description

SIGA develops and supplies TPOXX, an antiviral stockpiled by governments for smallpox preparedness, and operates a government-focused commercial model. While focused on a different threat, SIGA exemplifies the public-health stockpiling business model USIL targets for ARS countermeasures.

Market position
Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

USIL Therapeutics

Radioprotective Medical Countermeasuresusil-therapeutics.com

USIL Therapeutics is a Luxembourg-based biotechnology company founded in 2025 developing first-in-class radioprotective medical countermeasures (UT-241 auto-injector and UT-242 IV infusion) for Acute Radiation Syndrome, serving defence ministries, first responders, civil protection agencies, and healthcare systems in Europe and allied regions.

USIL Therapeutics firmographics

Firmographics
Name
USIL Therapeutics
Legal name
USIL Therapeutics S.A.
Website
https://usil-therapeutics.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
USIL Therapeutics is a Luxembourg-based biotechnology company founded in 2025 developing first-in-class radioprotective medical countermeasures (UT-241 auto-injector and UT-242 IV infusion) for Acute Radiation Syndrome, serving defence ministries, first responders, civil protection agencies, and healthcare systems in Europe and allied regions.
Ownership category
akta.pro rank

USIL Therapeutics industry classification

Industry
Product category
Radioprotective Medical Countermeasures
NAICS
Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAGAJ
Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radioprotective countermeasures
  • Radiation therapeutics
  • Medical countermeasures
  • Biodefense pharmaceuticals
  • Radiological preparedness

Where USIL Therapeutics is headquartered

Location

Headquarters

HQ city
Luxembourg
HQ country
Luxembourg
HQ region
Europe

Offices1 record

Markets served

USIL Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Medical Countermeasure Sales to Government/Institutional Buyers: Revenue from selling radioprotective medical countermeasures (UT-241 and UT-242) to defence ministries, first responders, civil protection agencies, hospitals, and emergency response systems. As a pre-revenue company (founded 2025), commercial revenue is anticipated post-2029 market entry.
  2. Licensing Royalties: Portfolio of multiple patents covering a radioprotective molecule with protection across EU, US, and Japan may generate licensing revenue from third-party commercialization rights.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

USIL Therapeutics product offering

Product offering

Core offering

USIL Therapeutics develops first-in-class whole-body radioprotective medical countermeasures for Acute Radiation Syndrome (ARS). Its pipeline includes UT-241, a ready-to-use intramuscular auto-injector designed for rapid field deployment by first responders and military personnel, and UT-242, an intravenous formulation for prolonged hospital-based therapeutic coverage. The dual-use platform addresses both acute high-dose radiation exposure and prolonged lower-dose radiation scenarios relevant to defence, civilian preparedness, and space missions.

Differentiator

Problem solved

Functional benefit

Brands

  • UT-241: IM Auto-Injector - a ready-to-use integral drug-device combination for rapid intramuscular administration, designed for time-critical scenarios involving first responders and exposed populations.
  • UT-242

Products and services

  • UT-241 IM Auto-Injector

Quantifiable outcome

  • Phase one pre-clinical trials completed with FDA review confirming safety for human administration
  • +2 more outcomes

Companies that use USIL Therapeutics

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

USIL Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

USIL Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • European Space Agency (ESA)coreStrategic or Co-development PartnerUSIL Therapeutics selected by ESA for in-orbit validation mission aboard the International Space Station. The study evaluates USIL's whole-body radioprotection approach under microgravity and elevated cosmic radiation to assess stability, biological response, and performance in space-relevant conditions. ESA-funded project supports dual-use development across spaceflight, defence, and civilian preparedness.
  • YURI (Yuri Gravity)coreStrategic or Co-development PartnerPartnership with YURI for ISS validation mission. YURI is a Luxembourg company specializing in payloads to Low Earth Orbit. Stefan Dimitrov-Lübcke, YURI LUX Managing Director, serves as Space Advisor to USIL Therapeutics.
  • French Alternative Energies and Atomic Energy Commission (CEA)coreStrategic or Co-development PartnerTESAR project consortium partner coordinated by USIL. CEA brings expertise in alternative energies and atomic energy research. The TESAR project delivers the first universal medical countermeasure for acute radiation syndrome fully developed and manufactured within Europe.
  • European CommissioncoreStrategic or Co-development PartnerUSIL holds two formal mandates within the European Commission's Joint Industrial Cooperation Forum (ICF) under HERA. TESAR project awarded multi-million EUR grant and STEP Seal under EU4Health Programme scoring 93/100. Selected participant in European Defence Fund Resilience 2026 work programme and EUDIS Business Accelerator Cohort 2.
  • SpaceXminorStrategic or Co-development PartnerCollaboration mentioned for ISS testing of the compound on International Space Station for potential space applications protecting astronauts and pilots.
  • NATO Support and Procurement Agency (NSPA)coreStrategic or Co-development PartnerAlignment with NATO procurement frameworks through NSPA for access to NATO-aligned stakeholders across Europe. Company positioned for institutional integration within defence coordination frameworks.
  • European Health Emergency Preparedness and Response Authority (HERA)coreStrategic or Co-development PartnerICF operates under HERA authority. USIL contributes to working groups addressing supply-chain resilience, manufacturing readiness, innovation, access, and strategic preparedness for medical countermeasures, supporting EU Medical Countermeasures Strategy implementation.

Scale indicators7 records

USIL Therapeutics competitors and assessment

Company assessment

Emerging players

  • Soligenix: Soligenix is a late-stage biopharmaceutical company developing medical countermeasures for radiation injury (e.g., SGX301 for cutaneous radiation injury) and other biodefense indications. Comparable as a countermeasure-focused specialty biotech pursuing government procurement pathways, though smaller and less capitalized than USIL's institutional backers.
  • Tonix Pharmaceuticals: Tonix is developing countermeasures for radiation and biodefense indications alongside its CNS pipeline, pursuing government contracts similar to USIL's strategy. Smaller and earlier stage than USIL but operates in an overlapping medical countermeasure regulatory and procurement space.

Broad incumbents

  • Bavarian Nordic: Bavarian Nordic is an established vaccine and biodefense company with government stockpiling contracts (e.g., smallpox, Ebola) and European institutional backing. Comparable as a European-headquartered biodefense countermeasure supplier leveraging both EU and US procurement channels.
  • Landauer: Landauer is a long-standing provider of radiation dosimetry and monitoring solutions used across medical, nuclear energy, and defence settings. Comparable as a radiation-safety incumbent serving the institutional customers USIL also targets, though via monitoring services rather than pharmaceutical countermeasures.
  • Emergent BioSolutions: Emergent is a publicly traded, established biodefense company with a broad portfolio of medical countermeasures (anthrax vaccines, smallpox therapies, etc.) and deep government procurement relationships. It represents the incumbent model USIL aspires to scale into across the radiological countermeasure niche.
  • Mirion Technologies: Mirion is a global incumbent in radiation safety, detection, dosimetry, and shielding products serving nuclear energy, defence, and medical markets. While Mirion sells equipment and services rather than drugs, it serves the same customer base (defence ministries, civil protection agencies, nuclear operators) and frames the broader radiation preparedness market USIL addresses.
  • SIGA Technologies: SIGA develops and supplies TPOXX, an antiviral stockpiled by governments for smallpox preparedness, and operates a government-focused commercial model. While focused on a different threat, SIGA exemplifies the public-health stockpiling business model USIL targets for ARS countermeasures.

Direct peers

  • Humanetics Corporation: Humanetics is the most direct comparable, developing BIO 300, a small-molecule radioprotectant intended to address acute radiation syndrome and radiation injury for military and civilian applications. Both companies target the same ARS unmet need with similar regulatory pathways (FDA, BARDA, DoD stockpiling).

Market position

Customer concentration

USIL Therapeutics social profiles

Digital presence

USIL Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

USIL Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

USIL Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

USIL Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USIL Therapeutics

What does USIL Therapeutics do?

USIL Therapeutics develops first-in-class whole-body radioprotective medical countermeasures for Acute Radiation Syndrome (ARS). Its pipeline includes UT-241, a ready-to-use intramuscular auto-injector designed for rapid field deployment by first responders and military personnel, and UT-242, an intravenous formulation for prolonged hospital-based therapeutic coverage. The dual-use platform addresses both acute high-dose radiation exposure and prolonged lower-dose radiation scenarios relevant to defence, civilian preparedness, and space missions.

Is USIL Therapeutics a public or private company?

USIL Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was USIL Therapeutics founded?

USIL Therapeutics was founded in 2025. It employs 1 to 10 people.

Where is USIL Therapeutics based?

USIL Therapeutics is headquartered in Luxembourg, Luxembourg, in the Europe region.

How does USIL Therapeutics make money?

Two revenue lines are on record. Medical Countermeasure Sales to Government/Institutional Buyers are the primary driver. The others are licensing Royalties.

Who are USIL Therapeutics's main competitors?

Emerging players on record are Soligenix and Tonix Pharmaceuticals. Broad incumbents are Bavarian Nordic, Landauer, Emergent BioSolutions, Mirion Technologies and SIGA Technologies. Humanetics Corporation is listed as a direct peer.

Does USIL Therapeutics have an API?

No public API is recorded for USIL Therapeutics.

What industry is USIL Therapeutics in?

USIL Therapeutics's product category is Radioprotective Medical Countermeasures. Its primary akta.pro industry code is HLAIAGAJ, Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine). Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SiliconluxembourgValentin Wiedling, Co-Founder & CDO, USIL Therapeutics - Silicon LuxembourgUSIL Therapeutics, co-founded by Valentin Wiedling, received a €5.2M EU grant to develop a dual-format treatment for radiological threats. The autoinjector and IV versions target soldiers, first responders, and hospitals, with regulatory filings planned for late 2027 and market entry in 2028/29.SiliconluxembourgUSIL Therapeutics Lands €5.2M EU GrantUSIL Therapeutics, a Luxembourg healthtech startup, secured a €5.2 million EU grant under the EU4Health Programme to develop Europe's first treatment for acute radiation syndrome. The grant covers €5.2M of an €8.7M project, with the autoinjector targeting market entry around 2029. The company also has an ESA-funded project testing its compound in orbit.MerkurUSIL Therapeutics sélectionnée pour un financement européen de €5.2MUSIL Therapeutics received a €5.2 million EU4Health grant from HERA to develop Europe's first sovereign radiological countermeasure. The project scored 93/100 and received the STEP label, with funds supporting development steps including formulation and safety studies. The treatment will be delivered via a simple auto-injector for emergency use.SiliconluxembourgWhat If Radiation Exposure Was No Longer A Death Sentence?USIL Therapeutics, a Luxembourg-based medical countermeasures firm founded in 2025, is developing a first-of-its-kind whole-body drug treatment for acute radiation syndrome, a condition currently classified as an official emergency gap by EU and US drug administrations with no effective treatment beyond symptomatic care. The company has completed phase one pre-clinical trials, received FDA review confirming safety for human administration, and aims to submit validation data by end of 2027 and enter the market in 2029 targeting defence ministries, first responders, and civil protection agencies in Europe, Ukraine, and Japan. USIL is also collaborating with the European Space Agency, Luxembourg company Yuri, and SpaceX to test the compound on the International Space Station for potential space applications protecting astronauts and pilots.